Genomic classification of serous ovarian cancer with adjacent borderline differentiates Ras pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6618-6630

  Emmanuel, Catherine ^a,b,c   Chiew, Yoke Eng ^a,c   George, Joshy ^d   Etemadmoghadam, Dariush ^d,e   Anglesio, Michael S ^d,l   Sharma, Raghwa ^b,f,g   Russell, Peter ^b,h   Kennedy, Catherine ^a,b,c   Fereday, Sian ^d   Hung, Jillian ^a,c   Galletta, Laura ^h   Hogg, Russell ^a,b   Wain, Gerard V ^a,b   Br, Alison ^a,b   Balleine, Rosemary ^b,c,f   MacConaill, Laura ⁱ   Palescolo, Emanuele ^i,m   Hunter, Sally M ^d   Campbell, Ian ^d,e   Dobrovic, Alexer ^d,e,j,n   Wong, Stephen Q ^d,e,j   Do, Hongdo ^d,n   Clarke, Christine L ^b,c   Harnett, Paul R ^a,b,c   Bowtell, David D L ^d,e,j,k   DeFazio, Anna ^a,b,c   more..

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Pathology West ICPMR Westmead   (Australia)

^g UNIVERSITY OF WESTERN SYDNEY   (Australia)

^h DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j LA TROBE UNIVERSITY   (Australia)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m JANSSEN RESEARCH FOUNDATION   (Belgium)

ⁿ LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROGESTERONE RECEPTOR; PROTEIN P53; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE K RAS; ONCOGENE N RAS; OVARY CANCER; PATHOGENESIS; TUMOR SUPPRESSOR GENE; CANCER GRADING; CANCER STAGING; CELL TRANSFORMATION; CLUSTER ANALYSIS; COPY NUMBER VARIATION; CYSTADENOCARCINOMA; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RAS PROTEINS; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84919675846     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1292     Document Type: Article

References (50)

1. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
2. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Ame J Surgical Pathol 2004;28:496-504.
3. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 1998;70:2-12.
4. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: anew model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
5. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
6. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.
7. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30: 2654-63.
8. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
9. Bonome T, Lee J-Y, Park D-C, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, lowgrade, and high-grade tumors of the ovary. Cancer Res 2005;65: 10602-12.
10. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008;6:1678-90.
11. Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih I-M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8.
12. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7.
13. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004;202:336-40.
14. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95: 484-6.
15. Boyd C, McCluggage WG. Low-grade ovarian serous neoplasms (lowgrade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol 2012;36:368-75.
16. Dehari R, Kurman RJ, Logani S, Shih I-M. The development of highgrade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: A morphologic and molecular genetic analysis. Am J Surgical Pathol 2007;31:1007-12.
17. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol 2004;23:265-72.
18. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008;108:510-4.
19. Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013;122:225-32.
20. Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a populationbased tumor registry. Int J Gynecol Pathol 2013;32:529-35.
21. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol 2013;130:660-6.
22. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14:134-40.
23. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
24. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23.
25. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009;4:e7887.
26. Mitchell G, Ballinger ML, Wong S, Hewitt C, James P, Young MA, et al. High frequency of germline TP53 mutations in a prospective adultonset sarcoma cohort. PLoS ONE 2013;8:e69026.
27. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
28. Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, et al. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep 2013;3:1659.
29. Popova T, Manié E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Ster M. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic pro files obtained by SNP arrays. Genome Biol 2009;10:R128.
30. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15.
31. Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci (USA) 2005;102:15545-50.
32. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, et al.DNAreplication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009;150:3318-26.
33. Rustin G, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419-23.
34. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS ONE 2011;6: e28250.
35. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-42.
36. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M, et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-7.
37. Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol 2013;128:371-6.
38. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013;14:853-62.
39. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16: 267-82.
40. Quddus MR, Rashid LB, Hansen K, Sung CJ, Lawrence WD. Highgrade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman. Histopathology 2009;54:771-3.
41. Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 1993;53:4138-42.
42. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012;18:5806-15.
43. Dokianakis DN, Varras MN, Papaefthimiou M, Apostolopoulou J, Simiakaki H, Diakomanolis E, et al. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clin Exp Metastasis 1999;17:293-7.
44. Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS ONE 2011;6:e24433.
45. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 2013;8:e72162.
46. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012;18:1503-10.
47. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-67.
48. Wada T, Yamashita Y, Saga Y, Takahashi K, Koinuma K, Choi YL, et al. Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. Int J Oncol 2009;35:973-6.
49. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van HerpenCM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56.
50. Hunter SM, Anglesio MS, Sharma R, Gilks CB, Melnyk N, Chiew YE, et al. Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Clin Cancer Res 2011;17:7273-82.